Shire Viropharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 71   

Articles published

VPHM 0.0000
price chart
Shire Buys ViroPharma for $4.2 Billion to Add Orphan Drug
Shire Plc agreed to buy ViroPharma Inc. for about $4.2 billion to gain treatments for rare diseases and ease dependence on its best-selling Vyvanse pill for attention deficit hyperactivity disorder.
Shire Buys ViroPharma for $4.2 Billion  Wall Street Journal
Shire Adding Cinryze to Rare Disease Portfolio via $4.2B Viropharma Buy  BioWorld Online
Related articles »  
Shire ViroPharma Blasts FTC's Citizen Petitions Suit
The FTC's suit alleges the company filed 46 baseless citizen petitions to delay entry of a generic version of its medication Vancocin D (FTC v. Shire ViroPharma, Inc., D. Del., No. 17-131, filed 2/7/17). The FTC claimed the company sought to protect ...
FTC accuses Shire ViroPharma of antitrust law violations
The Federal Drug Administration (FDA) has a practice where it refrains from approving generic applications of a drug if there are any pending citizen petition filings.
FTC charges Shire ViroPharma with abusing government processes to delay generics
The US Federal Trade Commission filed a complaint in federal district court charging Shire ViroPharma Inc with violating the antitrust laws by abusing government processes to delay generic competition to its branded prescription drug, Vancocin ...
Shire Unit Abused FDA Process With Most Filings Ever: FTC  Law360 (subscription)
UPDATE: US Files Antitrust Suit Against Shire (SHPG) Viropharma for Vancocin ...
Shire Files Infringement Suit On Same Day It Gets Drug Patent
Law360, New York (April 19, 2017, 1:38 PM EDT) -- Shire ViroPharma Inc. has sued CSL Behring LLC in Delaware federal court, alleging on the same day Shire received patent protection for a genetic disorder treatment that CSL's upcoming drug to treat the ...
What To Watch As FTC Opens New Front On Generic Delays
The FTC complaint lodged Tuesday pertains to 46 public filings, including 24 citizen petitions, that Shire PLC unit ViroPharma Inc. submitted in recent years in a bid to delay generic versions of its brand-name antibiotic Vancocin. The lawsuit is a ...
Shire Scorches FTC Suit Over Anti-Generic Petitions
Law360, New York (April 10, 2017, 8:25 PM EDT) -- Shire ViroPharma Inc. on Monday hammered a Federal Trade Commission antitrust suit over alleged abuse of the U.S.
$4.2 billion deal gives ViroPharma execs huge paydays
Shire's $4.2 billion acquisition of ViroPharma last month generated a huge payday for ViroPharma's top executives and board members.
ViroPharma surges, Shire settles as investors digest $4.2 billion merger
The 25% boost in ViroPharma Inc.'s share price stayed steady but support for Shire plc started to slide toward the breakeven point in Monday morning trades as investors digested the prospects of a merger between the two biotechnology companies.
Shire makes yet another move on its local office space
“We wanted to bring everyone together under one roof,” she said. The move isn't so far fetched. In 2013 Shire paid $4.2 billion for ViroPharma, which has a long-term lease on the Exton space - which allows Shire to put all its local employees under one ...